medicinal therapy products market are inadequate transparency, lack of funds, and regulatory
guidance for biopharmaceutical companies to manufacture these therapies and products.
Regional Analysis:
On the basis of geography, the global advanced medicinal therapy products are segmented into
North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is
expected to hold a dominant position in the global advanced medicinal therapy products market,
owing to the development in the field of cell and gene therapy. For instance, the innovative gene
therapy known as CAR-T or chimeric antigen receptor T-cell therapy harnesses the body’s own
immune cells to recognize and attack malignant cells. The T-cells are harvested and modified with a
new gene. The new gene contains a protein that directs the T-cells to target and kill leukemia cells
that have a specific antigen on the surface. Moreover, Food and Drug Administration (FDA)
approved first gene therapy in the U.S. in 2017, leading a new approach to the treatment of cancer
and other serious and life-threatening diseases. Moreover, Kymriah a cell based gene therapy has
also been approved by FDA in 2017 in the U.S. for the treatment of patients with a form of acute
lymphoblastic leukemia. Furthermore, Asia Pacific is expected to be the fastest growing region for
the global advanced therapy medicinal products market mainly due to rising number of skin burns
cases and cancer diseases.
Strategic acquisitions by Pfizer to develop gene therapies for the treatment of neuromuscular
conditions to enhance the competitive environment
The key players operating the advanced therapy medicinal products market include
• Uniqure,
• Pfizer,
• Bluebird Bio Inc.,
• BioMarin Pharmaceutical,
• Novartis AG,
• GE Healthcare,
• Shire Biotechnology,
• Kite Pharma.
The key players are focusing on strategic mergers and acquisition and development of innovative
products. For instance, Pfizer acquired Bamboo Therapeutics, a biotechnology company focused on
developing gene therapies for the treatment of patients with diseases related to neuromuscular
conditions and the diseases affecting central nervous system. The acquisition is expected to
significantly expand Pfizer’s expertise in gene therapy by providing clinical and pre-clinical assets
to balance the rare disease portfolio of company with advanced recombinant Adeno Associated
Virus vector design and production technology, which is fully functional phase I/II gene therapy
with manufacturing facilities.
Request For Customization @ https://www.coherentmarketinsights.com/insight/request-
customization/1101
Advanced Therapy Medicinal Products Market Taxonomy: